Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jun;51(6):e13496.
doi: 10.1111/eci.13496. Epub 2021 Feb 4.

Glucocorticoids for acute respiratory distress syndrome: A systematic review with meta-analysis and trial sequential analysis

Zhen Junhai  1 , Hu Bangchuan  2 , Gong Shijin  1 , Yan Jing  1 , Li Li  1
Affiliations
Meta-Analysis

Glucocorticoids for acute respiratory distress syndrome: A systematic review with meta-analysis and trial sequential analysis

Zhen Junhai et al. Eur J Clin Invest. 2021 Jun.

Abstract

Background: Glucocorticoids are some of the most commonly used drugs for patients with acute respiratory distress syndrome (ARDS). However, the curative effect and side effects of glucocorticoids in treating patients with ARDS remain controversial.

Methods: Three databases were searched until 2 July 2020, and randomized controlled trials (RCTs) that compared glucocorticoids versus other therapies in the treatment of ARDS were included in this meta-analysis. Trial sequential analysis (TSA) was conducted.

Results: A total of 14 RCTs with 1362 ARDS patients were assessed. Overall, no statistically significant effect was found on mortality between the glucocorticoid group and the control group of ARDS patients. In the subgroup analysis, no benefit of glucocorticoids for ARDS on mortality was found in trials stratified according to low versus high risk of bias or with vs. without a loading dose. As for the dose and length of therapy, no statistically significant effect was found on mortality with high-dose, short-course glucocorticoid therapy. However, lower-dose and longer-course therapy with glucocorticoids was found to decrease the mortality of ARDS patients (lower dose: RR = 0.69, 95% CI = 0.51-0.93, P = .02; longer-course therapy: RR = 0.60, 95% CI = 0.37-0.99, P = .04). The TSA showed that more trials are needed to confirm the results.

Conclusions: Longer- and lower-dose glucocorticoid treatment may improve the prognosis of ARDS patients, but RCTs with higher quality and larger sample sizes are needed to further clarify the clinical effects of glucocorticoids on ARDS.

Keywords: ARDS; glucocorticoids; intensive care unit; meta-analysis; systematic review; trial sequential analysis.

PubMed Disclaimer

References

REFERENCES

    1. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788-800.
    1. Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites?. Crit Care Med. 1998;26(4):627-630.
    1. Meduri GU. Pulmonary fibroproliferation and death in patients with late ARDS. Chest. 1995;107(1):5-6.
    1. Meduri GU, Tolley EA, Chinn A, et al. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1432-1441.
    1. Brigham KL, Bowers RE, McKeen CR. Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep. J Clin Investig. 1981;67(4):1103-1110.

MeSH terms

Substances

LinkOut - more resources